KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Change in Cash (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Change in Cash for 17 consecutive years, with -$5.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash fell 324.45% to -$5.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$129.0 million, a 88.99% increase, with the full-year FY2025 number at -$129.0 million, up 88.99% from a year prior.
  • Change in Cash was -$5.5 billion for Q4 2025 at Bristol Myers Squibb, down from $3.1 billion in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $4.0 billion in Q4 2023 to a low of -$5.5 billion in Q4 2025.
  • A 5-year average of -$237.8 million and a median of -$100.5 million in 2021 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: soared 594.42% in 2021, then plummeted 2230.26% in 2022.
  • Bristol Myers Squibb's Change in Cash stood at $437.0 million in 2021, then skyrocketed by 213.04% to $1.4 billion in 2022, then surged by 188.82% to $4.0 billion in 2023, then crashed by 37.89% to $2.5 billion in 2024, then plummeted by 324.45% to -$5.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BMY's Change in Cash are -$5.5 billion (Q4 2025), $3.1 billion (Q3 2025), and $1.7 billion (Q2 2025).